Juniper Pharmaceuticals Announces Regulatory Approvals for CRINONE® Progesterone Gel in Nine New EU Countries
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Canaccord Genuity Raises Price Target on Allergan (AGN) Following Announced Generics Sale
July 28, 2015 9:13 AM EDTCanaccord Genuity reiterated a Buy rating on Allergen (NYSE: AGN), and raised the price target to $396.00 (from $352.00), following the announced sale of its generics unit to Teva (NYSE: TEVA). Teva will acquire the unit for $40.5B.... More
Leerink Partners Raised Price Target on Allergan (AGN) to $388 Following TEVA Announcement
July 28, 2015 8:19 AM EDTAllergan (NYSE: AGN)
Leerink Partners reiterated an Outperform rating on Allergen (NYSE: AGN), and raised the price target to $388.00 (from $354.00), following this morning's announcement that TEVA will be acquiring AGNs Gx biz for $40.5B. Analyst Jason Gerberry views TEVA (OP) as the most suitable owner for the AGN's Gx assets.
Gerberry... More
